Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Sold by Ameriprise Financial Inc.

Ameriprise Financial Inc. cut its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 46.5% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 39,262 shares of the biopharmaceutical company's stock after selling 34,140 shares during the period. Ameriprise Financial Inc. owned about 0.07% of Agios Pharmaceuticals worth $1,290,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also made changes to their positions in the company. ArrowMark Colorado Holdings LLC lifted its stake in Agios Pharmaceuticals by 3.9% in the fourth quarter. ArrowMark Colorado Holdings LLC now owns 917,420 shares of the biopharmaceutical company's stock worth $30,146,000 after acquiring an additional 34,689 shares during the period. Gallagher Fiduciary Advisors LLC raised its holdings in shares of Agios Pharmaceuticals by 7.6% in the 4th quarter. Gallagher Fiduciary Advisors LLC now owns 11,110 shares of the biopharmaceutical company's stock valued at $365,000 after purchasing an additional 788 shares in the last quarter. Caligan Partners LP lifted its position in shares of Agios Pharmaceuticals by 8.0% in the 4th quarter. Caligan Partners LP now owns 626,280 shares of the biopharmaceutical company's stock worth $20,580,000 after purchasing an additional 46,563 shares during the period. Jane Street Group LLC boosted its stake in shares of Agios Pharmaceuticals by 58.8% during the fourth quarter. Jane Street Group LLC now owns 214,027 shares of the biopharmaceutical company's stock valued at $7,033,000 after purchasing an additional 79,222 shares in the last quarter. Finally, Northern Trust Corp increased its holdings in Agios Pharmaceuticals by 0.9% during the fourth quarter. Northern Trust Corp now owns 595,480 shares of the biopharmaceutical company's stock valued at $19,567,000 after buying an additional 5,372 shares during the period.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Scotiabank reduced their price objective on shares of Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating for the company in a research note on Friday, May 2nd. Wall Street Zen lowered Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Monday, May 19th. Finally, HC Wainwright initiated coverage on Agios Pharmaceuticals in a research note on Monday, February 24th. They set a "buy" rating and a $58.00 price objective for the company. One research analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $56.00.

Agios Pharmaceuticals Price Performance

NASDAQ AGIO traded up $0.66 on Wednesday, hitting $34.03. The stock had a trading volume of 649,232 shares, compared to its average volume of 673,314. The business's fifty day moving average price is $28.75 and its 200 day moving average price is $34.79. The stock has a market cap of $1.97 billion, a price-to-earnings ratio of 3.00 and a beta of 0.77. Agios Pharmaceuticals, Inc. has a 52-week low of $23.42 and a 52-week high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share for the quarter, topping analysts' consensus estimates of ($1.80) by $0.25. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. The firm had revenue of $8.73 million during the quarter, compared to analysts' expectations of $9.86 million. As a group, sell-side analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.

Insider Buying and Selling at Agios Pharmaceuticals

In other news, Director Jacqualyn A. Fouse sold 7,497 shares of the business's stock in a transaction dated Thursday, April 10th. The stock was sold at an average price of $25.90, for a total transaction of $194,172.30. Following the sale, the director now owns 149,220 shares in the company, valued at approximately $3,864,798. The trade was a 4.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.30% of the stock is currently owned by company insiders.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.